Immunic AG | Finanzwire

BRIEF

published on 02/26/2026 at 12:35, 4 hours 4 minutes ago

Immunic, Inc. Reveals 2025 Financial Outcomes and Strategic Plans

Multiple Sclerosis Vidofludimus Calcium Phase 3 Trials Immunic Financials Private Investment
PRESS RELEASE

published on 02/26/2026 at 12:30, 4 hours 9 minutes ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. reports year-end 2025 financial results, announces completion of private placement, and plans for MS programs advancement and commercial transition

Private Placement Immunic Inc. Multiple Sclerosis Year-end Results Commercial Transition
BRIEF

published on 02/17/2026 at 22:10, 8 days 18 hours ago

Immunic Secures Hefty Funding Through Oversubscribed Private Placement

Private Placement Biotechnology Multiple Sclerosis Trials Investor Participation Immunic Financing
PRESS RELEASE

published on 02/17/2026 at 22:05, 8 days 18 hours ago

Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic closes oversubscribed private placement financing of USD 200 million with potential for additional USD 200 million, aiming to fund phase 3 ENSURE trials and transition to commercialization

Private Placement Biotechnology Financing Immunic ENSURE Trials
BRIEF

published on 02/13/2026 at 12:35, 13 days 4 hours ago

Immunic Secures USD 400 Million to Advance Commercial Ambitions

Private Placement Biotechnology Leadership Changes Multiple Sclerosis Immunic AG
PRESS RELEASE

published on 02/13/2026 at 12:30, 13 days 4 hours ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic announces oversubscribed private placement of up to USD 400 million to accelerate transformation into commercial-stage company. New leadership appointments to propel growth

Private Placement Growth Leadership Immunic Commercial-stage
BRIEF

published on 02/04/2026 at 12:35, 22 days 4 hours ago

Immunic Unveils Promising Phase 2 Trial Results for Vidofludimus Calcium

Vidofludimus Calcium Phase 2 Trial Progressive Multiple Sclerosis ACTRIMS Forum 2026 Antiviral Effects
PRESS RELEASE

published on 02/04/2026 at 12:30, 22 days 4 hours ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic to present additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, reinforcing potential in Progressive Multiple Sclerosis. Latest research findings to be shared at event

Immunic Vidofludimus Calcium Progressive Multiple Sclerosis Phase 2 CALLIPER Trial ACTRIMS Forum 2026
BRIEF

published on 01/07/2026 at 12:35, 1 month 19 days ago

Immunic Reviews 2025 Progress and Sets Sights on Future Goals

Vidofludimus Calcium Neuroprotection Multiple Sclerosis Trials Immunic Accomplishments Biotechnology Milestones
PRESS RELEASE

published on 01/07/2026 at 12:30, 1 month 19 days ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic Inc. highlights its 2025 accomplishments & upcoming milestones including phase 3 trials for Vidofludimus Calcium in relapsing Multiple Sclerosis, positive data in Progressive MS, & potential for IMU-856 in weight management

Immunic Inc. Multiple Sclerosis Vidofludimus Calcium IMU-856 2025 Accomplishments

1 2 ... 9

Published on 02/26/2026 at 16:00, 39 minutes ago

Evergold Attending PDAC
Published on 02/26/2026 at 15:00, 1 hour 39 minutes ago

Golden Lake Announces Mailing of the Management Information Circular in Connection with its Annual General and Special Meeting of Securityholders to Approve the Acquisition by McEwen Inc.
Published on 02/26/2026 at 15:00, 1 hour 39 minutes ago

Norsemont Invites Shareholders and Investment Community To Visit Us at Booth 3035 at PDAC 2026 in Toronto, March 1–4
Published on 02/26/2026 at 15:00, 1 hour 39 minutes ago

Vox Royalty Acquires Producing Gold Royalty In New South Wales, Australia
Published on 02/26/2026 at 14:30, 2 hours 9 minutes ago

Loar Holdings Inc. Reports Q4 2025 and Full Year 2025 Record Results, and Upward Revisions to Full Year 2026 Outlook

View all ACCESSWIRE

Published on 02/26/2026 at 16:17, 22 minutes ago

EQS-Adhoc: Deutsche Beteiligungs AG resolves prolongation of current share buyback
Published on 02/26/2026 at 16:03, 35 minutes ago

Appointment of Non-Executive Director
Published on 02/26/2026 at 15:49, 49 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 02/26/2026 at 15:48, 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 02/26/2026 at 15:48, 51 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

View all EQS

Published on 02/26/2026 at 06:45, 9 hours 54 minutes ago

AXA: FY25 earnings
Published on 02/25/2026 at 20:06, 20 hours 32 minutes ago

Evolution within ENGIE governance
Published on 02/25/2026 at 20:03, 20 hours 35 minutes ago

ENGIE - Acquisition of UK Power Networks
Published on 02/25/2026 at 20:00, 20 hours 39 minutes ago

ENGIE FY 2025 results
Published on 02/25/2026 at 18:31, 22 hours 8 minutes ago

Saint-Gobain continues its development in construction chemicals by entering the Dominican Republic and strengthening its position in Benelux

View all LES ECHOS COMFI WIRE

News